Abstract Title:

Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition.

Abstract Source:

Cell Metab. 2015 Sep 1 ;22(3):399-407. PMID: 26331605

Abstract Author(s):

Tom J J Schirris, G Herma Renkema, Tina Ritschel, Nicol C Voermans, Albert Bilos, Baziel G M van Engelen, Ulrich Brandt, Werner J H Koopman, Julien D Beyrath, Richard J Rodenburg, Peter H G M Willems, Jan A M Smeitink, Frans G M Russel

Article Affiliation:

Tom J J Schirris

Abstract:

Cholesterol-lowering statins effectively reduce the risk of major cardiovascular events. Myopathy is the most important adverse effect, but its underlying mechanism remains enigmatic. In C2C12 myoblasts, several statin lactones reduced respiratory capacity and appeared to be strong inhibitors of mitochondrial complex III (CIII) activity, up to 84% inhibition. The lactones were in general three times more potent inducers of cytotoxicity than their corresponding acid forms. The Qo binding site of CIII was identified as off-target of the statin lactones. These findings could be confirmed in muscle tissue of patients suffering from statin-induced myopathies, in which CIII enzyme activity was reduced by 18%. Respiratory inhibition in C2C12 myoblasts could be attenuated by convergent electron flow into CIII, restoring respiration up to 89% of control. In conclusion, CIII inhibition was identified as a potential off-target mechanism associated with statin-induced myopathies.

Study Type : Human Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.